CAR-T: How far have we come and where are we going?

February 27, 2020

In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days. Parexel’s experts Mo Heidaran, Alexander Gee and host Alberto Grignolo, all part of our newly-integrated Regulatory & Access consulting unit, also weigh in on the current regulatory and reimbursement landscape for CAR-T and what we might look forward to in the future for this and other cell and gene therapies.

Previous Article
Putting the Pandemic in Plain Language
Putting the Pandemic in Plain Language

The COVID-19 pandemic has brought many negative feelings to the forefront of our everyday lives, including ...

Next Video
Rare Diseases: Aligning Expertise
Rare Diseases: Aligning Expertise

See how Parexel are bringing together regulatory and market access experts to help companies developing rar...


Register now for full access to all the content

First Name
Last Name
Company Name
Thank you for registering!
Error - something went wrong!